|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US4994443A
(en)
|
1982-12-20 |
1991-02-19 |
The Children's Medical Center Corporation |
Inhibition of angiogenesis
|
|
US5001116A
(en)
|
1982-12-20 |
1991-03-19 |
The Children's Medical Center Corporation |
Inhibition of angiogenesis
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US5391485A
(en)
|
1985-08-06 |
1995-02-21 |
Immunex Corporation |
DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
|
|
JPS63500636A
(ja)
|
1985-08-23 |
1988-03-10 |
麒麟麦酒株式会社 |
多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
|
|
US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
EP1134293A3
(en)
|
1992-03-04 |
2004-01-07 |
The Regents of The University of California |
Comparative genomic hybridization (CGH)
|
|
US5441050A
(en)
|
1992-12-18 |
1995-08-15 |
Neoprobe Corporation |
Radiation responsive surgical instrument
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US8143283B1
(en)
|
1993-03-01 |
2012-03-27 |
The Children's Medical Center Corporation |
Methods for treating blood-born tumors with thalidomide
|
|
US6114355A
(en)
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US5698579A
(en)
|
1993-07-02 |
1997-12-16 |
Celgene Corporation |
Cyclic amides
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
US5573758A
(en)
|
1995-04-28 |
1996-11-12 |
Allergan |
Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
|
|
US6207639B1
(en)
|
1996-07-12 |
2001-03-27 |
Mcgill University |
Compounds and methods for modulating neurite outgrowth
|
|
US6333307B1
(en)
|
1996-07-12 |
2001-12-25 |
Mcgill University |
Compounds and method for modulating neurite outgrowth
|
|
DE122007000079I2
(de)
|
1996-07-24 |
2010-08-12 |
Celgene Corp |
Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
|
|
US5798368A
(en)
|
1996-08-22 |
1998-08-25 |
Celgene Corporation |
Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
NZ334148A
(en)
|
1996-08-12 |
2001-12-21 |
Celgene Corp |
3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
|
|
US5955476A
(en)
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
|
US5874448A
(en)
|
1997-11-18 |
1999-02-23 |
Celgene Corporation |
Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
|
|
US6221585B1
(en)
|
1998-01-15 |
2001-04-24 |
Valigen, Inc. |
Method for identifying genes underlying defined phenotypes
|
|
TR200101502T2
(tr)
|
1998-03-16 |
2002-06-21 |
Celgene Corporation |
2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
|
|
US6680175B2
(en)
|
1998-05-05 |
2004-01-20 |
Adherex Technologies, Inc. |
Methods for diagnosing and evaluating cancer
|
|
US6472367B1
(en)
|
1998-05-05 |
2002-10-29 |
Adherex Technologies, Inc. |
Compounds and methods for modulating OB-cadherin mediated cell adhesion
|
|
EP1075494A2
(en)
|
1998-05-05 |
2001-02-14 |
Adherex Technologies, Inc. |
Compounds and methods for modulating nonclassical cadherin-mediated functions
|
|
US6277824B1
(en)
|
1998-07-10 |
2001-08-21 |
Adherex Technologies |
Compounds and methods for modulating adhesion molecule function
|
|
US6322962B1
(en)
|
1998-08-14 |
2001-11-27 |
Board Of Regents, The University Of Texas System |
Sterol-regulated Site-1 protease and assays of modulators thereof
|
|
US6927024B2
(en)
|
1998-11-30 |
2005-08-09 |
Genentech, Inc. |
PCR assay
|
|
CN1342146A
(zh)
|
1999-03-18 |
2002-03-27 |
塞尔基因公司 |
取代的1－氧代－和1,3－二氧代异吲哚啉及其在用于减少炎性细胞因子含量的药物组合物中的用途
|
|
WO2001042507A1
(en)
|
1999-12-09 |
2001-06-14 |
Advanced Research & Technology Institute |
Fluorescent in situ rt-pcr
|
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
CA2439402A1
(en)
|
2001-03-02 |
2002-09-12 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Pcr method
|
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
|
US20030194708A1
(en)
|
2002-04-10 |
2003-10-16 |
Minke Binnerts |
Human homolog of crossveinless materials and methods
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
AU2003247891A1
(en)
*
|
2002-07-08 |
2004-01-23 |
Merck & Co., Inc. |
Mitotic kinesin binding site
|
|
US20110070376A1
(en)
|
2002-09-09 |
2011-03-24 |
Reactive Surfaces, Ltd. |
Anti-fouling Paints & Coatings
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US7122799B2
(en)
|
2003-12-18 |
2006-10-17 |
Palo Alto Research Center Incorporated |
LED or laser enabled real-time PCR system and spectrophotometer
|
|
US7244759B2
(en)
|
2004-07-28 |
2007-07-17 |
Celgene Corporation |
Isoindoline compounds and methods of making and using the same
|
|
US20080051379A1
(en)
|
2004-12-01 |
2008-02-28 |
Trustees Of Boston University |
Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
|
|
NZ555886A
(en)
|
2004-12-01 |
2009-12-24 |
Celgene Corp |
Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders
|
|
EP1848433A2
(en)
|
2005-01-25 |
2007-10-31 |
Celgene Corporation |
Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
|
|
US7504225B2
(en)
|
2005-05-12 |
2009-03-17 |
Applied Genomics, Inc. |
Reagents and methods for use in cancer diagnosis, classification and therapy
|
|
US7776551B2
(en)
|
2005-07-12 |
2010-08-17 |
Ramot At Tel Aviv University Ltd. |
Methods and kits for diagnosing and treating mental retardation
|
|
UA91560C2
(ru)
|
2005-08-31 |
2010-08-10 |
Селджин Корпорэйшн |
Соединения ряда изоиндолимидов, их композиция и применение
|
|
US8445198B2
(en)
|
2005-12-01 |
2013-05-21 |
Medical Prognosis Institute |
Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
|
|
US20070128636A1
(en)
|
2005-12-05 |
2007-06-07 |
Baker Joffre B |
Predictors Of Patient Response To Treatment With EGFR Inhibitors
|
|
WO2007084992A2
(en)
|
2006-01-19 |
2007-07-26 |
The University Of Chicago |
Prognosis and therapy predictive markers and methods of use
|
|
EP2004193A2
(en)
|
2006-03-13 |
2008-12-24 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
|
WO2008005281A2
(en)
|
2006-06-30 |
2008-01-10 |
Rosetta Inpharmatics Llc |
Genes associated with chemotherapy response and uses thereof
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
WO2008039475A2
(en)
|
2006-09-26 |
2008-04-03 |
The Board Of Trustees Of The University Of Arkansas |
A gene expression profiling based identification of genomic signatures of multiple myeloma and uses thereof
|
|
ME02420B
(me)
|
2006-09-26 |
2016-09-20 |
Celgene Corp |
5-supstituirani derivati kinazolinona kao sredstva protiv raka
|
|
US20090075281A1
(en)
|
2007-07-10 |
2009-03-19 |
Regents Of The University Of California |
Mtbe genes
|
|
EP2235535B1
(en)
|
2007-12-07 |
2014-11-12 |
Celgene Corporation |
Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma
|
|
US20100021437A1
(en)
|
2008-04-07 |
2010-01-28 |
The McLean Hospital Corporation Whitehead Institute for Biomedical Research |
Neural stem cells derived from induced pluripotent stem cells
|
|
US9034319B2
(en)
|
2008-05-26 |
2015-05-19 |
Yeda Research And Development Co. Ltd. |
Methods of treating cancer of the central nervous system
|
|
WO2010017515A2
(en)
|
2008-08-08 |
2010-02-11 |
Integrated Diagnostics Inc. |
Breast cancer specific markers and methods of use
|
|
US20120035347A1
(en)
|
2009-04-14 |
2012-02-09 |
Schering Corporation |
Interferon-alfa sensitivity biomarkers
|
|
EP2436387B1
(en)
|
2009-05-25 |
2018-07-25 |
Celgene Corporation |
Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
|
|
CN102753187A
(zh)
|
2009-06-03 |
2012-10-24 |
戴瑟纳制药公司 |
肽-dicer底物试剂及其特异性抑制基因表达的方法
|
|
CA2774871C
(en)
|
2009-10-20 |
2018-05-29 |
Tokyo Institute Of Technology |
Screening method utilizing thalidomide-targeting factor
|
|
PL3202460T3
(pl)
|
2010-02-11 |
2019-12-31 |
Celgene Corporation |
Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
|
|
KR20130038838A
(ko)
|
2010-03-12 |
2013-04-18 |
셀진 코포레이션 |
레날리도미드, 및 예측 인자로서 유전자 및 단백질 바이오마커를 사용한 비호지킨 림프종의 치료 방법
|
|
EP2619574B1
(en)
|
2010-09-15 |
2020-10-28 |
Almac Diagnostic Services Limited |
Molecular test for predicting responsiveness to dna-damage therapeutic agents in individuals having cancer
|
|
DK2683708T3
(da)
|
2011-03-11 |
2018-01-29 |
Celgene Corp |
Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
|
|
US9662319B2
(en)
|
2011-03-11 |
2017-05-30 |
Mayo Foundation For Medical Education And Research |
Methods and materials for assessing responsiveness to lenalidomide, thalidomide, and/or other thalidomide analogs
|
|
PH12013501837A1
(en)
|
2011-03-11 |
2013-11-18 |
Celgene Corp |
Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
|
|
AU2012249491B2
(en)
|
2011-04-29 |
2016-12-15 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
|
EP2705370A2
(en)
|
2011-05-06 |
2014-03-12 |
Xentech |
Markers for cancer prognosis and therapy and methods of use
|
|
ES2872967T3
(es)
*
|
2012-06-29 |
2021-11-03 |
Celgene Corp |
Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
|
|
AU2013299627C1
(en)
|
2012-08-09 |
2018-05-31 |
Celgene Corporation |
Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
|
WO2014028445A2
(en)
|
2012-08-14 |
2014-02-20 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
|
EP2892537A1
(en)
|
2012-09-10 |
2015-07-15 |
Celgene Corporation |
Methods for the treatment of locally advanced breast cancer
|
|
US20150051283A1
(en)
|
2013-06-14 |
2015-02-19 |
Complexa, Inc. |
Composition and method for inhibition of pkng from mycobacterium tuberculosis
|
|
US20160282354A1
(en)
|
2013-11-08 |
2016-09-29 |
The Broad Institute, Inc. |
Compositions and methods for selecting a treatment for b-cell neoplasias
|
|
WO2015085172A2
(en)
|
2013-12-06 |
2015-06-11 |
Celgene Corporation |
Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
|
|
EP3827836A1
(en)
|
2014-06-27 |
2021-06-02 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US9713375B1
(en)
|
2015-02-26 |
2017-07-25 |
Brett Einar Rahm |
Collapsible portable table
|
|
WO2017117118A1
(en)
|
2015-12-28 |
2017-07-06 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|